Powered by HealthTechMovers.com
We added 6 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
Bio-Techne, TECH
Summary: Bio-Techne Corporation is a global life sciences company. It develops, manufactures, and sells biotechnology products and clinical diagnostic controls. It provides proteins, such as cytokines, growth factors, and enzymes; antibodies, including polyclonal and monoclonal antibodies; immunoassays comprising quantikine kits; and clinical diagnostic immunoassay kits. The Company also offers flow cytometry products; natural and synthetic chemical compounds; hematology controls and calibrators; and hematology control products. Bio-Techne Corporation, formerly known as Techne Corporation, is headquartered in Minneapolis, Minnesota.
- Last Price: $361.12
- Price Change: -$14.03, -3.74%
- Yearly Gain: -18.85%
- Market Cap: $14.72B
- P/E Ratio: 56.606
Here are 3rd party ratings for TECH:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Buy, Top 33% (84 out of 252)
What is the sentiment on the street regarding Bio-Techne ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Very High
- Insider Signal: Neutral
- Investor Sentiment: Positive
- Hedge Fund signal: Very Positive
If you are interested in TECH or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on TECH before you decide to make any investment.
Click here for chart >>
Natera, NTRA
Summary: Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California.
- Last Price: $50.82
- Price Change: -$1.34, -2.57%
- Yearly Gain: -54.58%
- Market Cap: $5.02B
- P/E Ratio: -8.592
Here are 3rd party ratings for NTRA:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 39% (99 out of 252)
What is the sentiment on the street regarding Natera ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Positive
- Hedge Fund signal: Very Positive
If you are interested in NTRA or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on NTRA before you decide to make any investment.
Click here for chart >>
Inari Medical, NARI
Summary: Inari Medical, Inc. is a commercial-stage medical device company committed toward developing products to treat and change the lives of patients suffering from venous diseases. Its initial product offering comprises 2 minimally-invasive, novel catheter-based mechanical thrombectomy devices. It built its products purposely on the basis of the specific characteristics of the venous system and the treatment of the two distinct indications of venous thromboembolism or VTE (deep vein thrombosis and pulmonary embolism/ PE). Its FlowTriever product is the first thrombectomy system, which is FDA-cleared, used for the treatment of PE. Its advanced systems & processes to control the key relationships between its sales representatives and treating physicians like cardiologists, radiologists, helps it to quickly iterate products, launch and execute physician education and training programs and scale its sales organization. The company markets and sells its products to hospitals across the U.S.
- Last Price: $82.13
- Price Change: -$1.29, -1.55%
- Yearly Gain: -12.43%
- Market Cap: $4.43B
- P/E Ratio: -288.55
Here are 3rd party ratings for NARI:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 40% (100 out of 252)
What is the sentiment on the street regarding Inari Medical ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Positive
- Hedge Fund signal: Very Positive
If you are interested in NARI or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on NARI before you decide to make any investment.
Click here for chart >>
Aldeyra Therapeutics, ALDX
Summary: Aldeyra Therapeutics, Inc. is a biotechnology company. The company's products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts.
- Last Price: $7.45
- Price Change: $0.25, 3.47%
- Yearly Gain: -26.30%
- Market Cap: $419.77M
- P/E Ratio: -6.335
Here are 3rd party ratings for ALDX:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 36% (90 out of 252)
What is the sentiment on the street regarding Aldeyra Therapeutics ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Neutral
If you are interested in ALDX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on ALDX before you decide to make any investment.
Click here for chart >>
Concert Pharma, CNCE
Summary: Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States.
- Last Price: $6.88
- Price Change: $0.26, 3.93%
- Yearly Gain: 85.95%
- Market Cap: $240.50M
- P/E Ratio: -1.941
Here are 3rd party ratings for CNCE:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 36% (90 out of 252)
What is the sentiment on the street regarding Concert Pharma ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Very High
- Insider Signal: Positive
- Investor Sentiment: Positive
- Hedge Fund signal: Neutral
If you are interested in CNCE or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on CNCE before you decide to make any investment.
Click here for chart >>
Chimerix, CMRX
Summary: Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina.
- Last Price: $2.44
- Price Change: $0.08, 3.39%
- Yearly Gain: -63.86%
- Market Cap: $206.35M
- P/E Ratio: -2.034
Here are 3rd party ratings for CMRX:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Buy, Bottom 44% (142 out of 252)
What is the sentiment on the street regarding Chimerix ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Neutral
If you are interested in CMRX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on CMRX before you decide to make any investment.
Click here for chart >>
Thanks for reading!